lactoferrin and bpc 157 BPC-157 Delayed Lactoferrin as a regenerative agent:

The ultimate goal is consistent, effective dosing with minimal waste

1995, 15(suppl 2):13.Google Scholar 44.Stabl, M, Biziere, K, Schmid-Burgk, W, Amrein, R

Annaliesa Anderson, Pfizers senior vice president and head of vaccine research and development, touted the benefits of Penbrayawhich combines components from two other meningococcal vaccines, Trumenba and Nimenrixsaying the new vaccine has the potential to protect more adolescents and young adults from this severe and unpredictable disease by providing the broadest meningococcal coverage in the fewest shots. Approval for Penbraya was granted based on positive results from Phase II and III trials, including a Phase III study that sought to determine the immunologic noninferiority of the vaccine against meningococcal vaccines currently available in the U.S

The development of novel therapeutics to address such complex tissue damage is therefore of high medical importance